Scleroderma

Current Problems in Dermatology

Volumn 12, Issue 2, 2000, Pages 95-102

  Falanga, Vincent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOBENZOIC ACID; ANTIMALARIAL AGENT; CALCITRIOL; CHLORAMBUCIL; CISAPRIDE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DILTIAZEM; ETRETINATE; FLUOROURACIL; GAMMA INTERFERON; KETOTIFEN; METHOTREXATE; NIFEDIPINE; NITRATE; PENICILLAMINE; PENTOXIFYLLINE; PHENYTOIN; PRAZOSIN; PREDNISONE; PROSTACYCLIN; RELAXIN; RESERPINE; TRANSFORMING GROWTH FACTOR BETA;

BORRELIA BURGDORFERI; FIBROBLAST; PATHOGENESIS; PORPHYRIA CUTANEA TARDA; PUVA; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN GRAFT; SKIN ULCER; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING;

EID: 0034064848     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-0486(00)90051-6     Document Type: Review

References (52)

1. Medsger TA Jr. Systemic sclerosis. In: Koopman WH, editor. Arthritis & allied conditions. Baltimore: Williams & Wilkins; 1997. p 1433-55.
2. Uitto J, Jimenez S. Fibrotic skin diseases. Clinical presentations, etiologic considerations, and treatment options. Arch Dermatol 1990;126:661-4.
3. Blauvelt A, Falanga V. Idiopathic and L-tryptophan associated eosinophilic fasciitis before and after L-tryptophan contamination. Arch Dermatol 1991;127:1159-66.
4. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Eng J Med 1994;331:1286-92.
5. Brunet CL, Sharpe PM, Ferguson MWJ. Inhibition of TGF-β3 (but not TGF-β1 or TGFβ2) activity prevents normal mouse embryonic palate fusion. Int J Dev Biol 1995;39:345-55.
6. Murata H, Zhou L, Ochoa S, et al. TGF-β3 stimulates and regulates collagen synthesis through TGF-β1 dependent and independent mechanisms. J Invest Dermatol 1997;108:258-62.
7. Varga J. Recombinant cytokine treatment for scleroderma: can the antifibrotic potential of interferon-gamma be realized clinically? Arch Dermatol 1997;133:637-42.
8. Key G, Becker MH, Baron B, et al. New Ki-67 equivalent murine monoclonal antibodies (MIB1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68:629-36.
9. Artlett CM, Smith BJ, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Eng J Med 1998;338:1186-91.
10. Kahari VM, Sandberg M, Kalimo H, et al. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988;90:664-70.
11. Falanga V, Zhou L, Takagi H, et al. Human dermal fibroblasts derived from single cells are heterogeneous in the mRNA levels of alpha 1(I) procollagen and TGF-beta 1. J Invest Dermatol 1995;105:27-31.
12. Falanga V, Martin TA, Takagi H, et al. Low oxygen tension increases mRNA levels of alpha 1(I) procollagen in human dermal fibroblasts. J Cell Physiol 1993;157:408-12.
13. Falanga V, Yufit T. Low oxygen tension increases collagen synthesis through the action of TGF-β1. J Invest Dermatol 1999;112:83(abstract).
14. Falanga V. Localized scleroderma. Med Clin North Am 1989; 73:1143-56.
15. Buechner SA, Winkelmann RK, Lautenschlager S, et al. Localized scleroderma associated with Borrelia burgdorferi infection; clinical, histologic, and immunohistochemical observations. J Am Acad Dermatol 1993;29:190-6.
16. Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol 1991;13: 334-41.
17. Asbrink E, Hederstedt B, Hovmark A. The spirochetal etiology of acrodermatitis chronica atrophicans. Acta Derm Venereol (Stockh) 1984;64:506-12.
18. Aberer E, Neumann R, Stanek G. Is localised scleroderma a borrelia infection? Lancet 1985;II:278.
19. Raguin G, Boisnic S, Souteyrand P, et al. No evidence for a spirochaetal origin of localized scleroderma. Br J Dermatol 1992;127:218-20.
20. Lupoli S, Cutler SJ, Stephens CO, et al. Lyme disease and localized scleroderma: no evidence for a common aetiology. Br J Rheumatol 1991;30:154-6.
21. Ross SA, Sanchez JL, Taboas JO. Spirochetal forms in the dermal lesions of morphea and lichen sclerosus et atrophicus. Am J Dermatopathol 1990;12:357-62.
22. Schempp C, et al. Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol 1993;100: 717-20.
23. Meis JF, Koopman R, Van Bergen B, et al. No evidence for a relation between Borrelia burgdorferi infection and old lesions of localized scleroderma (morphea). Arch Dermatol 1993;129:386-7.
24. Falanga V, Medsger TA, Reichlin M, et al. Linear scleroderma; clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986;104:849-57.
25. Falanga V. Fibrosing syndromes of childhood. In: Advances in Dermatology. St. Louis: Mosby Year Book; 1991; Vol 6. p 145-59.
26. Falanga V, Medsger TA. D-Penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990;126:609-12.
27. W'orle B, Hein R, Krieg T, et al. Cyclosporin in localized and systemic scleroderma: a clinical study. Dermatologica 1990;181:215-20.
28. Zarfonetis CJD. Antifibrotic therapy with POTABA. Am J Med Sci 1964;80:550.
29. Neldner KH. Treatment of localized linear scleroderma with phenytoin. Cutis 1978;22:569-72.
30. Neuhofer J, Fritsch P. Treatment of localized scleroderma and lichen sclerosus with etretinate. Acta Derm Venereol (Stockh) 1984;64:171-4.
31. Humbert PG, Dupond JL, Rochefort A, et al. Localized scleroderma: response to 1,25-dihydroxyvitamin D3. Clin Exp Dermatol 1990;15:396-8.
32. Greenberg SA, Falanga V. Localized cutaneous sclerosis. In: Sontheimer RD, Provost TT, editors. Cutaneous manifestations of rheumatic diseases. Philadelphia: Williams & Wilkins; 1996. p. 141-55.
33. Milan MF, Bennett JE. Scleroderma en coup de sabre. Ann Plast Surg 1983;10:364-70.
34. Kerscher M, Meurer M, Sander C, et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 1996;132:1280-2.
35. Hulshof MM, Pavel S, Breedveld FC, et al. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994;130:1290-3.
36. Hunzelmann N, Anders S, Fierlbeck G, et al. Double blind placebo controlled study of intralesional IFN-γ for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36:433-5.
37. Seyger MM, van den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998;39:220-5.
38. Joly P, Bamberger N, Crickx B, et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow up study on 17 patients. Arch Dermatol 1994;130:663-4.
39. Peter RU, Ruzicka T, Eckert F. Low-dose cyclosporine A in the treatment of disabling morphea. Arch Dermatol 1991; 127:1420-1.
40. Kerscher M, Meurer M, Sander C, et al. PUVA bath photochemotherapy for localized scleroderma. Arch Dermatol 1996;132:1280-2.
41. 1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997;36:938-44.
42. Altman RD, Medsger TA Jr, Bloch DA, et al. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
43. Wigley FM, Wise RA, Seibold RJ, et al. Intravenous iloprost infusion in patients with RP secondary to systemic sclerosis. Ann Intern Med 1994;120:199-206.
44. Belch JJ, Capell HA, Cooke ED, et al. Oral iloprost as a treatment for Raynaud's syndrome: A double-blind multicentre placebo-controlled study. Ann Rheum Dis 1995;54: 197-200.
45. Falanga V, Margolis D, Alvarez O, et al. Healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 1998;134:293-300.
46. Falanga V, Bucalo B. The use of a durometer to assess skin hardness. J Am Acad Dermatol 1993;29:47-51.
47. Stone JH, Wigley FM. Management of systemic sclerosis: the art and science. Semin Cutan Med Surg 1998;17:55-64.
48. Clements PJ, Wong WK, Seibold RJ, et al. High-dose vs. low-dose penicillamine in early diffuse systemic sclerosis (Ssc) trial: analysis of trial. Arthritis Rheum 1997;40: S854.
49. Siebold JR, Korn J, Simms R, et al. Controlled trial of recombinant human relaxin in diffuse scleroderma. Arthritis Rheum 1997;40:S557.
50. Rook, AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Arch Dermatol 1992;128:337-46.
51. Van den Hoogen FHJ, Boerbooms AMT, Swaak AJG, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Dermatol 1996;35:364-72.
52. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.